COMBINATION OF 5-HT-RECEPTOR ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITOR FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE IN SUBPOPULATION OF PATIENTS THAT ARE CARRIERS OF ApoE4 ALLELES Russian patent published in 2022 - IPC A61K31/4045 A61K31/445 A61P25/28 

FIELD: medicine; pharmaceutics.

SUBSTANCE: first invention is the use of a combination of 5-HT₆-receptor antagonist, which is N-(2-(6-fluoro-1H-indole-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamin or its pharmaceutically acceptable salt, and acetylcholinesterase inhibitor, which is donepezil or its pharmaceutically acceptable salt, for the treatment of Alzheimer’s disease, where a patient is a carrier of one or two ApoE4 alleles. The second invention is the use of a pharmaceutical composition containing the specified combination for the treatment of Alzheimer’s disease, where a patient is a carrier of one or two ApoE4 alleles. The third invention is a method for the treatment of Alzheimer’s disease, at which a patient is a carrier of one or two ApoE4 alleles and is subjected to the treatment with acetylcholinesterase inhibitor, which is donepezil or its pharmaceutically acceptable salt, while the method includes the additional administration of 5-HT₆-receptor antagonist, which is N-(2-(6-fluoro-1H-indole-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamin or its pharmaceutically acceptable salt.

EFFECT: group of inventions provides for an increase in the efficiency of a combination therapy of Alzheimer’s disease for patients of a specific group (carriers of one or two ApoE4 alleles).

13 cl, 5 tbl, 3 ex